Purpose Triple-negative breast cancer (TNBC)/basal-like breast cancer (BLBC) is a highly aggressive form of breast cancer. We previously reported that a small molecule agonist ligand for the orphan nuclear receptor estrogen-related receptor beta (ERRβ or ESRRB) has growth inhibitory and anti-mitotic activity in TNBC cell lines. In this study, we evaluate the association of ESRRB mRNA, copy number levels, and protein expression with demographic, clinicopathological, and gene expression features in breast tumor clinical specimens. Methods ESRRB mRNA-level expression and clinical associations were analyzed using RNAseq data. Array-based comparative genomic hybridization determined ESRRB copy number in African-American and Caucasian women. Transcription factor activity was measured using promoter-reporter luciferase assays in TNBC cell lines. Semi-automatic quantification of immunohistochemistry measured ERRβ protein expression on a 150-patient tissue microarray series. Results ESRRB mRNA expression is significantly lower in TNBC/BLBC versus other breast cancer subtypes. There is no evidence of ESRRB copy number loss. ESRRB mRNA expression is correlated with the expression of genes associated with neuroactive ligand-receptor interaction, metabolic pathways, and deafness. These genes contain G/C-rich transcription factor binding motifs. The ESRRB message is alternatively spliced into three isoforms, which we show have different transcription factor activity in basal-like versus other TNBC cell lines. We further show that the ERRβ2 and ERRβsf isoforms are broadly expressed in breast tumors at the protein level. Conclusions Decreased ESRRB mRNA expression and distinct patterns of ERRβ isoform subcellular localization and transcription factor activity are key features in TNBC/BLBC.
Introduction
Breast cancer is the most commonly diagnosed cancer in women and is the number two cause of cancer-related death [1] . Breast cancer subtypes are predominantly classified by two methods: immunohistochemistry (IHC) or gene expression. IHC tests for three proteins: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor two (HER2), and based on the expression of these three receptors, patients are classified as having ER+, HER2 overexpressing, or triple-negative breast cancer (TNBC). Patients who are diagnosed with TNBC are clinically defined as lacking ER, PR, and HER2 [2] . Gene expression profiling uses a 50-gene panel to determine if a breast cancer is one of 5 intrinsic, or Pam50 subtypes: luminal A, luminal B, HER2-enriched, normal-like, and basal-like breast cancer (BLBC) [3, 4] . In clinic, TNBC and BLBC largely converge [5] , with ≥ 80% of patients with TNBC also categorized as having BLBC. TNBC/BLBC is a biologically aggressive subtype of breast cancer with characteristic high genomic instability [6] . It is diagnosed more frequently in African-American (AA) women with much worse prognosis than Caucasian/White (CW) women [7] .
Since patients diagnosed with TNBC have tumors that lack ER and HER2, they are unresponsive to ER and HER2targeted therapies. Patients must instead be given systemic chemotherapy, which is accompanied by toxic side effects [8] . Due to the aggressive nature of TNBC, it is important to identify new prognostic marker genes capable of defining targets and conversely subtypes within TNBC. Historically, nuclear receptors (NRs) have been great targets for cancer treatment, such as the ER in ER+ breast cancer. The NR superfamily consists of many members including orphan NRs, ONRs [9] , which are defined as lacking any known endogenous ligands. One ONR subgroup contains what are known as the estrogen-related receptors (ERRs), named for their resemblance to the ER, although they do not bind or respond to estrogen [9] . ERR beta (ESRRB, ERRβ), which is alternatively spliced, is one of the first discovered ONRs and is known to have important functions in development [10] . Our lab and others have previously shown the function of ERRβ in cancer. Our 2016 publication showed that patients with BLBC whose tumors have high ESRRB mRNA expression have significantly improved distant-metastasisfree and recurrence-free survival in comparison to patients with low expression [11] . Previous publications have shown that patients with BLBC overall have tumors with significantly lower ESRRB mRNA expression in comparison to other breast cancer subtypes [12, 13] .
The goal of the present study is to (1) define ESRRB expression levels in breast cancer, specifically in BLBC and TNBC; (2) determine how DNA copy number and protein levels are modulated in various datasets to determine if the previously observed decrease in ESRRB is caused by copy number loss and the effects of decreased mRNA on protein expression and function; (3) characterize clinical correlations found in breast cancer. We show that ESRRB mRNA expression is significantly lower in patients with BLBC/ TNBC and that there is no observed decrease in DNA copy number. ERRβ splice variants have differential transcription factor activity in TNBC cell lines. Lastly, we also show that ERRβ splice variant protein levels are different in breast cancer patient samples depending on the IHC subtype. Patients with HER2 or TNBC have similar ERRβ protein expression and cellular localization versus patients with ER+. Our study supports further investigation into the establishment of ERRβ as a TNBC/BLBC therapeutic target or prognostic marker, and as a tool to provide more insights into this aggressive cancer and its mechanisms of progression.
Materials and methods

In silico analyses
Illumina HT 12 gene array data from the Molecular Taxonomy of Breast Cancer International Consortium (META-BRIC) study was analyzed via KM plotter [14] using a subset of patients who did not receive systemic treatment. A total of 300 patients (145 luminal A, 85 luminal B, 22 HER2, 48 basal-like) were included in the hazard ratio analysis.
RNA-sequencing (RNAseq) data were obtained from two publically available datasets: the Sweden Cancerome Analysis Network-Breast (SCAN-B) [15, 16] and The Cancer Genome Atlas, TCGA [17] . Gene expression profiles of GSE96058 (https ://www.ncbi.nlm.nih.gov/geo/query /acc.cgi?acc=GSE96 058) were downloaded from Gene Expression Omnibus (GEO) database for the SCAN-B data analyses. This SCAN-B cohort contained 3273 samples (136 were replicates) analyzed by Illumina paired-end RNAseq and expression estimation. These data come from Sweden and country law states that the submitter cannot provide raw sequence data in a public repository as sequencing may contain personally identifiable information and hereditary mutations. Data were processed as previously described [15, 16] and gene expression data were generated as fragments per kilobase of transcript per million, FPKM (expression measurement + 0.1 FPKM followed by log 2 transformation). Clinical information was publically available on GEO Accession Viewer and kindly provided in a comprehensive, table format by Dr. Lao Saal (Lund University, Sweden). TCGA raw, processed, and clinical data were obtained from the GDC Legacy Archive (https ://porta l.gdc.cance r.gov) and accessed using TCGABiolinks.
Gene expression analysis was performed using Rstudio (version 3.6.0) and Bioconductor. Gene expression levels, measured as FPKM, were determined for all breast cancer patient tumors as two datasets: Pam50 subtypes reported by the authors, or IHC subtypes parsed out using clinical information. Overall survival (OS) was determined using survminer. Differentially expressed genes (DEGs) were detected using edgeR. Genes with p < 0.05 and fold change ≥ 2 were considered significant (Table S1 ). Pathway and represented disease analyses were performed on overexpressed DEGs using KEGG pathway analysis [18, 19] . TNBC subtypes were determined using Vanderbilt's TNBC type tool [20, 21] .
For SCAN-B data, Cox regression was used to determine correlations between ESRRB expression and clinical characteristics. For promoter analysis, Bioconductor was used to isolate DEGs found within annotated genome UCSC, hg19 and search the promoter region of these genes, − 4000 to + 500 bp from the transcription start site for enriched short, ungapped, redundant sequences of up to 8 base pairs using Discriminative Regular Expression Motif Elicitation (DREME, [22] ). The primary set of sequences was shuffled to create a control set. Significantly overrepresented motifs were determined using Fisher's exact test. We then used TOMTOM [23] to compare our overrepresented motifs to the publically available JASPAR CORE database [24] which provides the binding preferences of a large database of known transcription factors. Source code for SCAN-B and TCGA analyses can be found at https ://githu b.com/Riggi nsLab GU/Rmark down/blob/maste r/SCANB %20ana lysis .Rmd and https ://githu b.com/Riggi nsLab GU/Rmark down/ blob/maste r/TCGA%20ana lysis .Rmd.
Array comparative genomic hybridization
The 106-patient cohort of 37 Caucasian (CW) and 69 AA patients with TNBC and non-TNBC (NTN) was collected and processed as previously described by Sugita et al. [25] : 17 CW/TNBC; 20 CW/NTN; 39 AA/TNBC; 30 AA/NTN. Copy number was determined from ESRRB probes on the Agilent SurePrint aCGH platform. Log 2 intensity > 3 was defined as amplification, ≥/≤ 0.25 were defined as copy number gain and loss, respectively, and ≥ 3 was defined as deletion. PRISM 8.0 (GraphPad, San Diego, CA) was used for all statistical analyses of copy number and clinical demographic information.
Cell culture
HCC1806 breast cancer cells were purchased from ATCC (Manassas, VA). MDA-MB-453 breast cancer cells were a gift from Dr. Anna Riegel (Lombardi Comprehensive Cancer Center, LCCC). BT549, MCF7, and MCF10A breast cancer cells were obtained from the LCCC Tissue Culture Shared Resource. Cells were routinely tested for Mycoplasma spp. and tested negative and fingerprinted using 9 standard STR loci and Y chromosome-specific amelogenin to verify authenticity. All cells were maintained in a humid carbon dioxide (CO 2 ) incubator, 95% air:5% CO 2 . HCC1806 and MDA-MB-453 cells were grown in improved minimal essential media (IMEM; Life Technologies, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (FBS, purchased from LCCC Tissue Culture Shared Resource). BT549 cells were cultured in IMEM with 10% FBS and 10 µg/mL insulin (purchased from Life Technologies, Grand Island, NY).
Plasmids and transfection
The psG5 empty vector, ERRβsf (murine ERRβ, > 90% homology to human ERRβ, Addgene #52188), ERRβ2 (Addgene #52186), and ERRβ-∆10 (Addgene #52187) constructs have all been published previously [11, 26] . The ERRE-luciferase (Addgene #37851) and p21-luciferase (Addgene #21723) have been previously described [26] . Plasmids were introduced using Mirus TransIT-X2 Dynamic Delivery System (Mirus Bio LLC; MIR600Q) according to manufacturer's instructions.
Dual-luciferase promoter-reporter assays
Cells were seeded into 24-well plastic tissue culture dishes at 150,000 cells per well on day 0. On day 1, cells were transfected using 500 ng DNA/well (137 ng receptor; 360 ng luciferase reporter plasmid; 3 ng Renilla control) for 24 h. On day 2, media containing the transfection complexes was removed and fresh media was added to the cells. On day 3, at 48 h, cells were harvested for luciferase assay (https :// www.prome ga.com/prod ucts/reporter-assays-and-transfection/reporter-assays/dual_luciferase-reporter-assay-system/) according to the manufacturer's instructions. Luciferase activity was normalized to Renilla. All experiments were performed 3-5 times.
Western blotting and antibodies
Lysate collected for dual-luciferase activity assay were run on 4-12% poly acrylamide gels using electrophoresis for 90 min. After protein was transferred to nitrocellulose membranes, the membranes were blocked for 1 h in 5% non-fat dry milk in Tris-buffered saline with Tween-20 (TBST) and probed overnight at 4 °C with ERRβ #PP-H6707-00 (cl.07) 1:500. All membranes were then re-probed with loading control β-tubulin at 1:10:000 for 1 h at room temperature or overnight at 4 °C.
Horseradish peroxidase enzyme-conjugated anti-mouse whole immunoglobulin (IgG) secondary antibody (GE #NXA931 Buckinghamshire, UK) was used the following day at 1:5000 for 1 h at room temperature. The membranes were then imaged for enhanced chemiluminescence (ECL, Denville Scientific, Holliston, MA) on the Amersham Imager 600 (GE Life Sciences).
Image analysis and statistical analysis of in vitro work
Images and figures were composed using Adobe Photoshop, Illustrator, and InDesign. FIJI was used to perform densitometry on imaged blots. Statistical analyses of dualluciferase activity assay and western blot densitometry were done using PRISM 8.0 (GraphPad, San Diego, CA).
Invasive ductal carcinoma breast cancer TMA series
The Histopathology and Tissue Shared Resource (HTSR) at Georgetown University Medical Center's LCCC constructed the Invasive Ductal Carcinoma Tissue Microarrays (TMAs) series. The cohort consists of 150 patients with breast cancer distributed as 50 patients each on a series of 3 TMAs. All patients are research-consented through the HTSR, the Survey, Recruitment and Biospecimen Shared Resource (SRBSR), and/or Indivumed groups under the following respective Georgetown University Medical Center IRB Protocols 1992-048, Pr0000007, and 2007-345. The 50 patients for each TMA were grouped based on the following molecular subtypes of their tumors: ERα+ TMA (> 10% ERα positivity, PR+/−, HER2−), HER2+ TMA (ER+/−, PR+/−), and TNBC TMA. The TMAs were stained for ERα, PR, HER2, Ki67, and pancytokeratin in a single multiplexed assay. High-resolution images are available for all stained cores as well as quantification of percentage positive for ER, PR, and Ki67 and threshold analysis for HER2 positivity. Two cores for each patient are available side by side on the TMA. Each TMA has matching biological and immunological controls including tonsil, spleen, testis, reduction mammoplasty (benign breast), placenta, and six well-characterized breast cancer cell lines. Inclusion criteria for the TMA were female patients diagnosed with invasive ductal carcinoma with at least 3-year clinical follow-up (majority with 5-year follow-up, or otherwise deceased) with a primary breast cancer surgical resection at MedStar Georgetown University Hospital (MGUH) between 2004 and 2014. Exclusion criteria were male patients, patients diagnosed with ductal carcinoma in situ only or lobular carcinoma, known BRCA or familial mutation carriers, or evidence of neoadjuvant therapy. Racial distribution of the patients was 64% White/Caucasian, 26% Black/AA, 10% other or unknown, allowing for support for projects analyzing racial disparities. Clinical, treatment, and follow-up data were retrieved by the Innovation Center for Biomedical Informatics (ICBI) from the MGUH Cancer Registry. Pathology data were manually extracted from the original surgical pathology reports. All demographic, clinical, pathology, and available follow-up data were deidentified and uploaded into a REDCap database for query and analysis. High-resolution images of hematoxylin and eosin-stained cores are available for all cores on the TMA.
Immunohistochemical staining
IHC staining of breast cancer tissue was performed for ERRβ. Five micron sections from formalin-fixed paraffinembedded tissues were de-paraffinized with xylenes and rehydrated through a graded alcohol series. Heat-induced epitope retrieval (HIER) was performed by immersing the tissue sections in target retrieval solution, low pH (Dako) in the PT link (Dako). IHC staining was performed using the VectaStain Kit from Vector Labs according to manufacturer's instructions. Briefly, slides were treated with 3% hydrogen peroxide, avidin/biotin blocking, and 10% normal goat serum and independently exposed to primary antibodies for ERRβ2-cl 0.07, 1:150, 1:240 (R&D Systems, #PP-H6707-00) and ERRβsf-cl 0.05, 1:150 (R&D Systems, #PP-H6705-00) for 1 h at room temperature. Slides were exposed to appropriate biotin-conjugated secondary antibodies (Vector Labs), VectaStain ABC reagent, and DAB chromagen (Dako). Slides were counterstained with hematoxylin (Fisher, Harris-modified hematoxylin), blued in 1% ammonium hydroxide, dehydrated, and mounted with Acrymount. Control tissues with the primary antibody omitted were used as negative controls. Images of the full TMA slide stained for of hematoxylin and eosin, ERRβsf-cl 0.05, and ERRβ2-cl 0.07 are available on figshare (https ://doi.org/10.6084/m9.figsh are.99928 91.v1).
Scanning and analysis using Vectra3
Stained slides were scanned using the Vectra3 Multi-Spectral Imaging Microscope with Vectra and Phenochart software (Perkin Elmer). Every available TMA core was imaged as a 3 × 3 composite image to capture almost the entire core in one image. The scanned images were analyzed in inForm software version 2.3 (Akoya). The inForm software is trained to identify individual cells within the TMA core by hematoxylin staining and intensity, average cell size, and cell splitting algorithms. Brown DAB staining that overlapped with hematoxylin staining was identified by the software as being a nuclear staining, while staining without overlap with the nuclear signal was considered cytoplasmic. In this way, nuclear versus cytoplasmic staining was differentiated. An average of 11,000 cells were counted per TMA core.
Statistical analysis of tissue microarray data
To prepare for statistical analysis, individual cores were manually examined and matched to their corresponding coordinates defined by Vectra3 software. Any cores missing more that 50% of tissue due to adipose tissue or folding were omitted from final analysis. The two cores from each patient were individually scored and then averaged to determining the 50 scores per TMA slide used in the analyses.
ERRβ-clone 07 (recognizes ERRβ2), ERRβ-clone 05 (recognizes ERRβsf), and their ratio, as well as demographic variables were summarized by using mean (standard deviation, sd) and median (interquartile range, IQR) for continuous variables and frequency and percentage for categorical variables. Kruskal-Wallis tests were used to test whether median ERRβ2 and ERRβsf expression levels, and their ratio, were significantly different among the three IHC receptor subtypes. To assess whether the expression of each isoform was significantly different among the three IHC subtypes while considering lymph node status, race, and age, and if there was any interaction between IHC subtype and demographic variables, we first made a logit transformation of ERRβ-clone 07 and ERRβ-clone 05 which achieved approximate normality. Then two-way ANOVA was used for analysis following ANOVA procedure. If a significant difference was observed, pairwise comparisons were performed by Dwass, Steel, Critchlow-Fligner multiple comparison procedure (DSCF).
Nuclear staining and cytoplasmic staining were summarized by IHC subtype using mean (sd) and median (IQR). Spearman's correlation coefficient was calculated to measure the association between the nuclear and cytoplasmic staining in each IHC subtype.
All tests were two-sided at a significant level 0.05. No method was used for adjusting multiple comparisons. All analyses were performed using SAS 9.4 and Rstudio (Version 0.99.902) software.
Results
Low ESRRB mRNA expression is associated with shorter overall survival
We previously published that high expression of ESRRB mRNA is associated with improved recurrence-free and distant-metastasis-free survival in a merged cohort of patients with BLBC from multiple independent studies [11, 14] . Here, we analyzed the association of ESRRB mRNA expression with OS by analyzing Illumina HT 12 gene array data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) study [27] . Importantly, the subset of patients selected for this analysis did not receive systemic treatment, providing a more compelling link between ESRRB expression and clinical outcome that is not confounded by treatment effect. We found that low ESRRB expression (defined as below median) is associated with significantly shorter OS only in patients with BLBC ( Fig. 1 ).
ESRRB mRNA expression levels are significantly decreased in BLBC and TNBC, but not associated with age, grade, or lymph node status
We used two large, publicly available RNAseq datasets-SCAN-B [15, 16] and TCGA [17]-to analyze ESRRB mRNA expression in association with demographic, clinicopathologic, and gene expression features. ESRRB expression as FPKM was measured in both datasets in patients stratified by either IHC or Pam50 breast cancer subtypes for analysis ( Fig. 2) . In SCAN-B, ESRRB expression was significantly lower in patients with BLBC compared to patients with luminal A or normal-like breast cancer ( Fig. 2a ). ESRRB expression was also significantly lower in patients with TNBC versus patients with ER+ and ER+/HER2+ breast cancer (Fig. 2b) . In TCGA data, we confirmed the previously published findings of Garattini et al. [13] and found that patients with BLBC had significantly lower ESRRB expression compared to patients with luminal A breast cancer ( Fig. 2c ). Like the SCAN-B cohort, patients classified as TCGA-TNBC also had significantly lower ESRRB expression compared to patients with ER+ and ER+/HER2+ breast cancer ( Fig. 2d ).
SCAN-B is a 3273-patient dataset collected in Sweden starting in 2010 [15, 16] . Biospecimens were collected and RNAseq was performed on biopsy cores as previously described [15] . Comprehensive clinical and demographic information was also collected, allowing for analysis of ESRRB association with these data for both the Pam50 and IHC subtypes. Analysis of Pam50 subtype revealed patients with BLBC were significantly younger than patients with luminal A, luminal B, and HER2 breast cancer (Fig. S1a ), a characteristic commonly found in patients with BLBC, while analysis by IHC subtype showed that patients with HER2 were significantly younger than patients with ER+ breast cancer ( Fig. S1b) .
We also assessed the correlation between ESRRB high and low mRNA expression and clinical characteristics. Across the entire SCAN-B cohort, there was a weak but statistically significant positive correlation between ER (ESR1) and ESRRB mRNA expression (p = 8.1e−05, Fig. 2e ). There was no significant correlation between ESRRB expression and age ( Fig. 2f ). Filtered datasets were split into tertiles with the top third considered ESRRB "high" expression and the lower third considered "low" expression. Analysis within the Pam50 and IHC subtypes showed that there was no significant difference in age between patients with high versus low ESRRB within the Pam50 subtypes (not shown). There also were no significant differences observed in lymph node status, Nottingham grade (NHG), endocrine treatment, or chemotherapy treatment between patients with high versus low ESRRB. However, receipt of chemotherapy was negatively correlated with age at diagnosis (p < 5e −107 ) and positively associated with NHG (p < 6.7e −127 ), which is broadly reflective of clinical management decisions made in the treatment of younger women and higher grade disease (Fig. 2g) [28] .
OS was assessed comparing patients with ESRRB high versus ESRRB low breast cancer tumors (upper vs. lower tertiles) of all subtypes, BLBC, and TNBC from TCGA and SCAN-B datasets. There was no statistically significant difference in OS found for patients with ESRRB high versus low in SCAN-B or TCGA data ( Fig. S1c-h) . This is likely because in SCAN-B, > 80% of the patient population remain alive, while in the TCGA dataset filtering out patients with TNBC or BLBC leaves a low number of patients with an event (n = 123/1098), decreasing the power of these analyses. Though not statistically significant, patients with BLBC in the TCGA dataset with high ESRRB expression did trend toward better OS than patients with ESRRB low (hazard ratio = 2.13). Overall, these data confirm lower ESRRB expression in patients with TNBC or BLBC from two largescale cohorts but identify no statistically significant associations between ESRRB expression and age, grade, lymph node status, or treatment.
ESRRB does not exhibit copy number loss in TNBC
Next, we sought to determine if the observed decrease in ESRRB mRNA expression found in TNBC/BLBC may be due to copy number loss. We approached this by analyzing an independent, 106-patient cohort of Caucasian (CW) and AA patients with TNBC and non-TNBC (NTN; all other breast cancer subtypes, i.e., ER+ and HER2-amplified) using array comparative genomic hybridization (aCGH) as previously described by Sugita et al. [25] . ESRRB copy number was calculated and defined as deletion, loss, gain, or amplification, and demographic information was analyzed for associations with ESRRB copy number changes ( Fig. S2a-e ). Fisher's exact test showed that in our cohort, patients with TNBC had significantly higher grade than nontriple-negative (NTN) patients at diagnosis (p < 0.0001), indicating that our cohort is representative of the TNBC population ( Fig. 3a ). There were no significant differences observed between CW and AA patients with TNBC and NTN in relation to the total number of copy number alterations. However, > 75% of all patients showed copy number gain rather than loss at the ESRRB locus, 14q24.3 (Fig. 3b ).
Since self-reported race and ethnicity data are not always concordant with genotyping analyses, we also assessed ancestry informative markers (AIMs) and the ESRRB mRNA expression f ESRRB mRNA expression by age. g Correlation of ESRRB high and low expression, frequency of node status, age at diagnosis, NHG, endocrine treatment, and chemotherapy in all breast cancer patients in dataset. Spearman correlation. White spaces were not significantly different. Light to dark colors, correlation observed and statistically significant, p < 0.001 ◂ distribution of ESRRB copy number in a small subset of our cohort [27, 29] . This 20-patient subset included 6 patients with TNBC and 14 patients with NTN and due to the small number is exploratory. Principal component analysis (PCA) of 3000 AIMs overlaid with self-reported ethnicity of our cases showed separation of distinct ancestral populations [25] when merged with two populations from the 1000 Genomes Project: African descent (AFR) and ad mixed American (AMR) (Fig. 3c) . The mean rank for ESRRB was markedly lower in the AA, but there was no statistically significant difference in the average ESRRB copy number in breast tumors from the AA women (clustered with the AFR group) versus the CW (clustered with the AMR group) (Fig. 3d ).
Differentially expressed genes (DEGs) in patients with tumors characterized by ESRRB high versus ESRRB low expression
We next identified DEGs in patients with tumors characterized by ESRRB mRNA-high versus ESRRB mRNA-low expression to determine what other genes are co-modulated with ESRRB expression. First, we compared tumors from patients that are ESRRB high and low (upper and lower tertiles, respectively) and assessed genes that were high in patients with ESRRB high (left/pink) and low in patients with ESRRB high (right/purple) (≥ 2-fold up-or down-regulated, p < 0.05, Fig. 4a-d ; Table S1 ). We determined the overlap of DEGs between datasets and between BLBC and TNBC, finding the most overlap within datasets ( Fig. 4e;  Fig. S3a, b) . Prior studies report that greater than 80% of patients with TNBC also have BLBC [5] and our analysis of the SCAN-B and TCGA datasets shows a similar overlap (Fig. S3c, d) . KEGG pathway analysis [18, 19] [30, 31] (Fig. 4f) .
We then searched for transcription factor binding motifs of up to 8 base pairs within the promoter region (− 4000 to + 500 bp from the transcription start site) of the enriched DEGs in the SCAN-B dataset [22] . DEGs in BLBC samples had 39 enriched motifs which aligned to 320 known transcription factors. TNBC samples had 40 enriched motifs which aligned to 611 known transcription factors (TOM-TOM [23] ; JASPAR [24] , Fig. S3e ). Top matches for both BLBC and TNBC in the SCAN-B dataset were extracted, E < 0.05. The top motifs found in BLBC and TNBC were GGC ACG TGCC and CCA CCG ACA, respectively. These motifs aligned to multiple known transcription factors, including basic helix-loop-helix (bHLH) and AP-2 motifs, both characterized as G/C-rich (Table 1 ).
ERRβ isoform transcription factor activity differs across cellular models of TNBC molecular subtypes
A key challenge in defining bona fide ESRRB target genes among DEGs from high-dimensional datasets is that ERRβ, at the protein level, is expressed as at least three distinct isoforms: ERRβsf, ERRβ2, ERRβ-Δ10 [32, 33] . These isoforms are produced via alternative splicing in which a genetic alteration at intron-exon boundaries, or splice sites, is altered at the mRNA level resulting in different proteins [34] . Two of these isoforms-ERRβsf and ERRβ2-have opposing functions in regulating cell cycle progression [11] , while less is known about ERRβ-Δ10 due to a lack of validated antibodies to detect this isoform at the protein level [35] . We first established basal level of two ERRβ isoforms-ERRβ2 and ERRβsf-in a panel of TNBC cell lines reflective of diverse TNBC subtypes. TNBC subtypes were initially defined as a step to further personalize medicine. There are six distinct TNBC subtypes based on gene expression and ontology [21, 36] . Cell lines representing five of the six subtypes, as well as non-transformed mammary epithelial cells MCF10A and ER+ cells MCF7, were probed for ERRβ2 and ERRβsf using two monoclonal antibodies we have previously characterized as selective for each isoform [11, 26] . TNBC cell lines had a trend toward lower ERRβ protein levels in comparison to the MCF10As and MCF7s (Fig. 5a-c; Fig. S4a, b ). HCC1806s (basal-like 2, BL2) had the lowest ERRβ2:ERRβsf ratio, while MDA-MB-453s (luminal androgen receptor, LAR) had the highest ratio, though these differences did not reach statistical significance (Fig. 5c ). Consistent with this, assessment of TNBC subtypes, classified using TNBCtype [20, 21] , at the mRNA level in SCAN-B tumor also showed no significant differences in ESRRB expression between the subtypes (Fig. S4c) . Analysis of publicly available gene expression data in cell lines showed similar ERRβ2 mRNA expression ( Fig. S4d, e ).
To measure transcription factor function of ERRβ isoforms, we overexpressed cDNAs for each isoform in three different TNBC cell lines and measured their ability to induce transcription from heterologous promoter-reporter constructs. The three cell lines used were HCC1806, MDA-MB-453, and BT549, representing three of six TNBC subtypes [21] . The promoter-reporter constructs contained sequences corresponding to two established ERRβ response elements: estrogen-related response element (ERRE, TNAAG GTC A) [37, 38] and specificity-protein-1 (SP1, (G/T)GGG CGG (G/A)(G/A)(C/T)) [39] (Fig. 5d ). SP1 was also one of the top motifs identified in the BLBC subtype from the SCAN-B dataset ( Table 1 ). In HCC1806 (BL2) cells, there was significantly higher activity of both the ERRE and SP1 response elements induced by all three splice variants in comparison to empty vector. ERRβsf had significantly higher activity on the ERRE than ERRβ2 or ERRβ-Δ10, while ERRβ-Δ10 had significantly higher activity on the SP1 response element than ERRβsf or ERRβ2. In MDA-MB-453 (LAR) cells, ERRβsf had significantly higher activity on both the ERRE and SP1 response elements, while ERRβ-Δ10 had significantly higher activity on SP1 in comparison to empty vector. In BT549 (mesenchymal-like, ML) cells, ERRβsf and ERRβ-Δ10 had significantly higher activity on both the ERRE and SP1 response elements in comparison to empty vector. For both MDA-MB-453s and BT549s, ERRβ2 had no significant transcription factor activity on either ERRE or SP1. Western blot analysis confirmed overexpression of ERRβ isoforms in transfected cells ( Fig. 5e-g) . These data suggest that patterns of ERRβ isoform transcription factor activity may differ between basal-like and other TNBC molecular subtypes.
ERRβ isoform expression in breast tumor tissue varies by IHC subtype
We next assessed the protein expression of ERRβsf and ERRβ2 isoforms in patient tissues from a 150-patient TMA assembled by the HTSR at Georgetown University Medical Center's LCCC. The TMA series consists of 50 invasive ductal carcinoma breast cancer patients each diagnosed with ER+, HER2 overexpressing, and TNBC IHC subtypes, with corresponding demographic and clinical information (race, pathological stage, age, treatment, Table 2 ). Post antibody optimization (Fig. S5a) , consecutive sections of the TMA were stained for one of two antibodies: ERRβ-clone 05 (recognizes ERRβsf) or ERRβ-clone 07 (recognizes ERRβ2). Cells were phenotyped and staining was quantified in a semi-automated fashion using the Vectra3 Multi-Spectral Imaging Microscope (Fig. 6a-c; Fig. S5b ). Representative image shows the differential staining of the two antibodies (Fig. 6d ). Statistical analyses were performed to determine The median of ERRβ2, but not ERRβsf, expression was significantly different among the three IHC receptor subtypes: ER+, HER2, TNBC (p = 0.016). Post hoc analysis showed that ERRβ2 was significantly different between patients with ER+ and HER2 breast cancer (p = 0.017, Fig. 7a ; Table S2 .1). Median ERRβsf: ERRβ2 expression ratio was lowest in TNBC subtypes (indicating lower ERRβ2 or higher ERRβsf expression); however, this ratio was not statistically significantly different among the three IHC receptor subtypes (Fig. 7b) .
We next assessed statistical interactions and main effects of three variables: IHC subtypes (variable 1), lymph node status, race, or age (variable 2), and ERRβ status (variable 3). For ERRβ2 expression, there were no statistical interactions between the IHC subtypes and lymph node status, race, or age that affected ERRβ status. There was no significant main effect on ERRβ2 expression by IHC subtypes with lymph node status, or, by IHC subtypes with age. However, race did show a significant main effect (p = 0.024) or difference in ERRβ2 expression among the different races ( Fig. 7c ; Table S3 ). Follow-up post hoc Kruskal-Wallis found that the ERRβ2 median was significantly different among the three IHC subtypes in AA patients (p = 0.0312, Fig. 7d ). Further pairwise comparisons with DSCF method showed this observed difference was between patients with ER+ and TNBC (p = 0.0212, Fig. 7b, d ).
There were no significant statistical interactions between the IHC subtypes and lymph node status or age that affected ERRβsf status; however, we did see significant interaction effect with race (p = 0.009) indicating differential ERRβsf expression within the five races between the three IHC subtypes (Table S3 ; Fig. 7e ). This significant interaction was followed up with a Kruskal-Wallis post hoc analysis which showed that median ERRβsf expression was significantly different among five races in the HER2 IHC receptor subtype (p = 0.0102). Follow-up pairwise comparisons showed that this significant difference was between AA and CW patients (p = 0.0282, Fig. 7f ).
We next analyzed the subcellular localization of ERRβsf and ERRβ2 isoforms among the different IHC subtypes. Previous studies have shown that ERRβsf and ERRβ2 have different localization and functions within cells [11] , with ERRβsf predominantly nuclear and ERRβ2 expressed in both the nucleus and cytoplasm. ERRβ2 had higher cytoplasmic versus nuclear staining in patients with ER+ compared to patients with HER2 or TNBC, while ERRβsf had both nuclear and cytoplasmic staining in all three IHC subtypes (Fig. 8a, b ; Table S2 .2). We performed Spearman rank analysis to measure the association between the nuclear and cytoplasmic staining of ERRβ2 and ERRβsf in each IHC subtype. In the ER+ group, both ERRβ2 and ERRβsf nuclear staining were significantly positively correlated with cytoplasmic staining (r = 0.945, p < 0.0001 and r = 0.488, p = 0.00038, respectively) meaning the expression of nuclear ERRβ2/ERRβsf increases when the value of cytoplasmic ERRβ2/ERRβsf increases. In the HER2 group, ERRβ2 nuclear staining was significantly negatively correlated with cytoplasmic staining (r = − 0.922, p < 0.0001), while ERRβsf nuclear staining was positively correlated with cytoplasmic staining (r = 0.928, p < 0.0001). In the TNBC group, ERRβ2 nuclear staining was also significantly negatively correlated with cytoplasmic staining (r = − 0.729, p < 0.0001), while ERRβsf nuclear staining was positively correlated with cytoplasmic staining (r = 0.93, p < 0.0001) (Fig. 8c ).
Discussion
In this study, we characterize ONR ESRRB/ERRβ copy number and expression and its clinical correlations in breast cancer. Patients with low ESRRB mRNA expression have significantly shorter OS. ESRRB mRNA expression is significantly lower in TNBC/BLBC versus other breast cancer subtypes, but not significantly associated with age, lymph node status, or grade. In an independent dataset, we find no evidence of ESRRB copy number loss in patients with TNBC, suggesting that reduced mRNA expression is driven by other mechanisms. We further find that ESRRB expression is correlated with that of genes associated with neuroactive ligand-receptor interaction, metabolic pathways, and deafness, and that these genes contain G/C-rich transcription factor binding motifs. We show that the ESRRB message, which is alternatively spliced into three distinct isoforms, leads to different isoform transcription factor activity in TNBC cell lines that are characterized as basal-like versus the mesenchymal or LAR subtype. Finally, we show in clinical samples that the ERRβ2 and ERRβsf isoforms are broadly expressed at the protein level.
We found that the loss of ESRRB mRNA in patients with TNBC/BLBC was not due to a loss of copy number, and in fact there was a gain in ESRRB copy number in all breast cancer subtypes. Though the copy number gain was not significant, it does suggest that there is a mechanistic variance occurring during transcription of this gene in breast cancer patients that drives the loss of mRNA that is consistently and significantly observed especially in TNBC/BLBC. While our ancestrality marker results were not significant, in the subset which had a small number of patients, we saw a trend toward reduced ESRRB copy number in AA versus CW patients which aligned with 1000 genome projects-defined AFR and AMR patients, respectively. This addresses a clinical diagnosis issue frequently encountered in which demographic information is misreported [40] . In this case, we looked at self-reported race in comparison to refined race and ethnic information from genotyping, and saw a difference in copy number that was not seen with only the self-reported race. The trend suggests that with a statistically powered analysis (more patients) we may see more definitive results. Our results suggest that there is value to the addition of ancestrality markers to future analyses. It may also address an issue with accessibility to race data. For example, because of the limited amount of clinical data on race, when we filter for AA patients with TNBC with expression of ESRRB there are < 29 out of the 1098 patients in TCGA. When looking at transcription factor activity we found that the three known splice variants ERRβsf, ERRβ2, ERRβ-Δ10 when exogenously expressed have differential activity on known ESRRB response elements. In basal-like TNBC cell line, BL2, ERRβsf had higher activity on the ERRE, while ERRβ-Δ10 had higher activity on the sp1 response element. Meanwhile in LAR and ML TNBC cell lines, ERRβsf and ERRβ-Δ10 had higher activity on both response elements, while ERRβ2 had no change in activity. The LAR and ML subtypes are consistent with our previous publication in which we showed that in a ER+ setting ERRβsf has higher activity on the ERRE while ERRβ2 shows no change in activity [11] . The difference in activity may be explained by the differing C-terminus of the splice variants. While all three isoforms share exons 3-9, ERRβsf is truncated at exon 9, ERRβ2 has exon 10 and part of 11, and ERRβ-Δ10 skips exon 10, but contains exons 11 and 12. Due to the different exon combinations, the three variants have different functional domains which may cause steric hindrance and thus may alter the binding of each variant to DNA. To further validate these findings, stable cell lines with inducible overexpression of ESRRB isoforms should be established. Transient overexpression limits the time frame in which experiments can be carried out to 24-72 h, with optimal expression ~ 48 h in the TNBC cell lines. Stable overexpression would allow us to further evaluate other features such as proliferation, cell death, migration, and invasion in association with overexpression of specific ESRRB isoforms. Non-transformed mammary epithelial cells MCF10As should also be established with both stable overexpression and knockdown/knockout with rescue.
To date, the small molecule agonist DY131 (DY) is one of the more promising ESRRB-targeting drugs [41] . Treatment with DY decreases cancer cell, but not non-transformed mammary epithelial cell, proliferation, induces apoptosis, and causes spindle polarity defects. This, paired with the knowledge that ERRβ2 mediates mitotic arrest, as well as localization of the ERRβ2 splice variant [11] , leads to the hypothesis that treatment with DY may target ERRβ2 preferentially in the cancer setting. Our finding in this work showing higher amounts of ERRβ2 compared to ERRβsf supports this hypothesis. This drug needs to be further studied and refined for use in humans. Using DY in conjunction with stable overexpression cell lines will strengthen our findings. This is the first reported comparative quantification of ERRβsf and ERRβ2 protein expression in IHC breast cancer subtypes. Our 150-patient TMA revealed that in all three IHC subtypes (ER+, HER2, TNBC) a higher percentage of tumor cells are ERRβ2+ than ERRβsf+. We established that ERRβ2 was significantly different between patients with ER+ or HER2, and that the ratio of ERRβ2:ERRβsf was lower in patients with TNBC than it was in patients with ER+ or HER2. Though this difference was not statistically significant, it did suggest that in the more aggressive breast cancer subtype there is either an increase in expression of the ERRβsf splice variant or a decrease in expression of the ERRβ2 splice variant. Our previous publications have led to the hypothesis that ERRβ-specific, ligand-mediated mitotic arrest is due to the ERRβ2 splice variant, and that the loss of this splice variant is an effect of the malignant transformation associated with TNBC/BLBC [11] .
We have previously published that in breast cancer cell lines ERRβ2 localizes to the cytoplasm and centrosomes in the nucleus while ERRβsf localizes in the nucleus [11] . We further looked at this localization to see if there were differences among the three IHC subtypes. We established that while in ER+ tumors there was a positive correlation between nuclear and cytoplasmic staining for ERRβ2 and ERRβsf, both HER2 and TNBC-clinically aggressive subtypes-showed a positive correlation for ERRβsf and a negative correlation for ERRβ2. Furthermore, ERRβ2 localized almost exclusively in the nucleus in both of those settings. The inconsistency from our previous findings points to the question of heterogeneity and how to best treat cancer patients based on the different cells within a tumor.
This study has provided insight into the expression of ERRβ and its implications in TNBC/BLBC, an aggressive subtype of breast cancer which, to date, does not have any targeted therapies. Limitations of our study include the underrepresentation of AA patients, a group that is disproportionally affected by this breast cancer subtype. Though the SCAN-B dataset is very large, it has limited racial and ethnic diversity. Our TMA had ~ 1/3 AA patients, which is an improvement over past studies, some of which did not include any AA patients. Additionally, we have shown the value ancestrality information can provide in lieu of selfreported race.
Another limitation of our analyses includes the inability to properly examine splice variant-specific ESRRB at the mRNA level. Due to the overall loss of ESRRB observed in the cancer setting, it is extremely difficult to look at individual isoform expression. To properly quantify splice variants at the RNA level, we would need to use ultra-deep RNAseq [42, 43] . This increases genome coverage and improves sequencing accuracy, providing assurance that we are accurately looking at isoform mRNA expression.
Future steps include in vitro validation of our DEG, pathway, and promoter analyses to further determine ESRRB coregulatory partners. As previously stated, the establishment of stable cell lines will be instrumental in these validation studies. With this information, ESRRB/ERRβ could serve as a future therapeutic target or as a biomarker in TNBC.
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